Abstract

One of the components that activate cannabinoids (CB) receptors is 11-hydroxy-Δ8-THC-dimethylheptyl (HU-210). The present study was conducted to evaluate the effectiveness of HU-210 treatment to cytokines profile and locomotor tests in the experimental autoimmune encephalomyelitis (EAE) model in the mice. A total of 48 male C57BL/6 mice were placed in 8 therapeutic groups. Mice were immunized with myelin oligodendrocyte glycoprotein (MOG) 35–55. When EAE was observed¸ HU-210 was subcutaneously administered in 3 groups with different doses: 3,10,30 mg/kg. Control groups were treated to vehicle or HU-210. Drug or vehicle was given once on the following days: 1, 3, 5, 7, 9, 11, 13, 15, 17. During the study clinical scores of disease and balance beam test were analyzed. After 17 days of treatment, the animals sacrificed and, TNFα, IL-12, IL-4 level in serum was measured using enzyme-linked immunosorbent assay (ELISA). Our results showed that HU-210-treated mice had significantly less clinical score of EAE than non-treated EAE induced mice (p<0.05). Data revealed that dose 30 mg/kg HU-210 in EAE induced mice significantly decreased serum TNFα, IL-12 (p<0.05). Also, Serum IL-4 levels increased significantly in mice receiving 3, 10, 30 mg/kg dose of HU-210 (p<0.05). Present study revealed the beneficial effects of HU-210 in the model of EAE, and suggests its potential use as a drug for the treatment of multiple sclerosis (MS).

Key words: Experimental autoimmune encephalomyelitis, 11-hydroxy-Δ8-THC-dimethylheptyl, cytokine, cannabinoids.